Zacks Investment Research Downgrades argenx (NASDAQ:ARGX) to Sell

Zacks Investment Research downgraded shares of argenx (NASDAQ:ARGX) from a hold rating to a sell rating in a research note released on Monday morning, Zacks.com reports.

According to Zacks, “argenx SE is a biopharmaceutical company. It focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company’s product pipeline consists of ARGX-113, ARGX-110 and ARGX-111 which are in clinical trials. argenx SE is based in Breda, the Netherlands. “

A number of other brokerages also recently issued reports on ARGX. UBS Group started coverage on argenx in a research report on Friday, June 18th. They set a buy rating and a $390.00 price objective for the company. Wedbush lowered their target price on argenx from $356.00 to $344.00 and set an outperform rating for the company in a report on Tuesday, June 8th. Morgan Stanley boosted their price objective on argenx from $321.00 to $324.00 and gave the company an overweight rating in a report on Tuesday, May 18th. Redburn Partners initiated coverage on argenx in a research report on Friday, April 23rd. They set a neutral rating on the stock. Finally, Kepler Capital Markets cut argenx to a hold rating in a research report on Sunday, May 16th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and eleven have given a buy rating to the company. The company currently has a consensus rating of Buy and an average price target of $330.21.

NASDAQ ARGX opened at $319.00 on Monday. argenx has a 12 month low of $212.66 and a 12 month high of $382.15. The firm has a 50 day moving average of $296.12. The firm has a market cap of $16.37 billion, a P/E ratio of -26.32 and a beta of 0.92.

argenx (NASDAQ:ARGX) last released its earnings results on Friday, May 14th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.14) by $2.33. The company had revenue of $167.42 million for the quarter, compared to analyst estimates of $39.04 million. argenx had a negative return on equity of 50.37% and a negative net margin of 298.93%. On average, analysts expect that argenx will post -12.98 EPS for the current fiscal year.

A number of large investors have recently bought and sold shares of the business. Sowell Financial Services LLC increased its holdings in shares of argenx by 458.8% in the first quarter. Sowell Financial Services LLC now owns 95 shares of the company’s stock worth $25,000 after purchasing an additional 78 shares during the last quarter. Bank of Montreal Can increased its stake in argenx by 75.3% during the first quarter. Bank of Montreal Can now owns 156 shares of the company’s stock worth $44,000 after acquiring an additional 67 shares during the last quarter. The PNC Financial Services Group Inc. boosted its position in shares of argenx by 69.6% during the first quarter. The PNC Financial Services Group Inc. now owns 212 shares of the company’s stock valued at $59,000 after buying an additional 87 shares during the period. JPMorgan Chase & Co. boosted its position in shares of argenx by 4,583.3% during the fourth quarter. JPMorgan Chase & Co. now owns 281 shares of the company’s stock valued at $82,000 after buying an additional 275 shares during the period. Finally, Quadrant Capital Group LLC boosted its holdings in shares of argenx by 38.6% in the first quarter. Quadrant Capital Group LLC now owns 309 shares of the company’s stock valued at $85,000 after purchasing an additional 86 shares during the period. 55.57% of the stock is currently owned by institutional investors and hedge funds.

About argenx

argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia.

Further Reading: How to Invest in a Bull Market

Get a free copy of the Zacks research report on argenx (ARGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for argenx (NASDAQ:ARGX)

Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.